LONDON--(BUSINESS WIRE)--The global adrenocortical carcinoma drugs market is expected to post a CAGR of more than 6% during the period 2019-2023, according to the latest market research report by Technavio.
A key factor driving the growth of the global adrenocortical carcinoma drugs market size is the advantages of novel drugs over chemotherapeutics. The adrenocortical carcinoma drugs market has witnessed the development of novel drugs to treat the condition, which are more efficacious than the treatment options currently available. Chemotherapeutics such as mitotane can cause major side effects including peripheral neuropathy and seizures. Furthermore, the treatment of adrenocortical carcinoma with chemotherapeutics has also shown a lower survival rate in patients. This is expected to increase the use of novel drugs, which are showing long-term efficacy and potential benefits in patients.
As per Technavio, the advances in imaging techniques for adrenal tumors will have a positive impact on the market and contribute to its growth significantly over the forecast period. This global adrenocortical carcinoma drugs market 2019-2023 research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.
Global Adrenocortical Carcinoma Drugs Market: Advances in Imaging Techniques for Adrenal Tumors
Over the years, there have been significant advances in imaging techniques for the detection of adrenal lesions. Various imaging techniques with enhanced diagnostic accuracy in a non-invasive manner have been developed for adrenocortical carcinoma. For instance, the multiphase computed tomography technique is one of the latest imaging techniques which can calculate both the absolute percentage and the relative percentage washout, which helps in identifying both benign and malignant lesions of the adrenal gland. This helps healthcare professionals in treating the patient effectively with the correct drugs. Thus, advances in imaging techniques for adrenal tumors will fuel the growth of the adrenocortical carcinoma drugs market during the forecast period.
“Apart from the advances in imaging techniques for adrenal tumors, other factors such as the increase in R&D, along with the rise in prevalence of genetic disorders will have a significant impact on the adrenocortical carcinoma drugs market growth during the forecast period,” says a senior analyst at Technavio.
Global Adrenocortical carcinoma drugs Market: Segmentation Analysis
This market research report segments the global adrenocortical carcinoma drugs market size by type (chemotherapy, and targeted therapy), and geographic regions (North America, Europe, Asia, and ROW).
The North American region led the adrenocortical carcinoma drugs market in 2018, followed by Europe, Asia and ROW respectively. The adrenocortical carcinoma drugs market report identifies factors such as the rising incidence of genetic syndromes, the approval of novel drugs, and the increased R&D of drugs to fuel the growth of the market in North America during the forecast period.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market size and forecast
Five Forces Analysis
- Regional comparison
- Key leading countries
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at email@example.com.